AI Terminal
Dr. Martens PLC
Board/Management Information • Feb 27, 2024
5055_rns_2024-02-27_f0fe577b-24b8-491e-bf32-b4869cce2b07.html
Board/Management Information
Open in ViewerOpens in native device viewer
National Storage Mechanism | Additional information 
RNS Number : 5012E
Dr. Martens PLC
27 February 2024
27 February 2024
Dr. Martens plc
CFO appointment update
Dr. Martens plc ('the Company') announces that Giles Wilson, who has been appointed to the role of Chief Financial Officer (CFO), will join the business and Board on 27th May 2024 and will present the FY24 results on 30th May 2024.
The Company also confirms that Giles and Katie Wilson, a person closely associated with him, have purchased a total of 57,400 shares in Dr. Martens plc on the open market since his appointment was first announced.
Enquiries
Investors and analysts
Bethany Barnes, Director of Investor Relations [email protected] +44 7825 187465
Beth Callum, Senior Investor Relations Analyst [email protected] +44 203 995 2644
Press
H/Advisors Maitland +44 207 379 5151
Katharine Spence +44 7384 535739
Gill Hammond, Director of Communications +44 7384 214248
About Dr. Martens
Dr. Martens is an iconic British brand founded in 1960 in Northamptonshire. Produced originally for workers looking for tough, durable boots, the brand was quickly adopted by diverse youth subcultures and associated musical movements. Dr. Martens has since transcended its working-class roots while still celebrating its proud heritage and, six decades later, "Docs" or "DM's" are worn by people around the world who use them as a symbol of empowerment and their own individual attitude. The Company is a constituent of the FTSE 250 index.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
BOAFZGZZVVDGDZM